JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Summary

This is a phase II, open, single-center clinical study to evaluate the efficacy and safety of JS001 combined with Axitinib in the treatment of advanced non-small cell lung cancer without activated EGFR mutation, ALK fusion and ROS fusion after or during first-line chemotherapy. About 50 subjects will be included in this study and will be treated with JS001 combined with acitinib. Each cycle is 21 days.

Timeline

Start

2020-08-31

Primary completion

2023-09-30

Completion

2023-12-31

Drugs

Indications